Yes, you can take empagliflozin with diuretics, but the combination is documented to carry a moderate interaction risk. According to source data from the National Library of Medicine, using empagliflozin together with diuretics increases urine volume and frequency, which can enhance the potential for volume depletion—meaning your body may lose too much water and electrolytes. Because of this, your doctor or pharmacist should monitor your fluid status and kidney function if you are taking both medications.
The documented interaction between empagliflozin and diuretics is classified as moderate in severity. The interaction record, sourced from the National Library of Medicine's drug labeling data, describes the concern as follows:
This classification means the interaction is clinically significant and warrants attention, but it does not mean the drugs cannot be used together—only that careful oversight is necessary. The source makes clear that volume status and kidney function are the key areas requiring monitoring.
Empagliflozin is a medication belonging to a class called SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors). It is used to help manage type 2 diabetes and certain heart and kidney conditions. The way empagliflozin works is distinct from many other diabetes medications: it causes your kidneys to allow more glucose (sugar) to be filtered into your urine. This helps lower blood sugar levels, but it also means more fluid is excreted in urine—a side effect that contributes to increased urination and fluid loss.
Diuretics are a broad class of medications that increase urine production. They are commonly prescribed for high blood pressure, heart failure, and fluid retention. Common diuretic types include thiazide diuretics (such as hydrochlorothiazide), loop diuretics (such as furosemide), and potassium-sparing diuretics (such as spironolactone). All work by different mechanisms, but they all ultimately increase the volume of urine your body produces.
The documented mechanism of this interaction is described as an additive diuretic effect. In plain language, this means that when you take empagliflozin and a diuretic together, both medications are independently increasing urine production. The effects do not cancel out or interact chemically; rather, they work in the same direction—toward increased urination and fluid loss. Think of it like two workers pushing the same heavy cart in the same direction: the combined force is stronger than either alone.
Volume depletion refers to loss of total body water and electrolytes (such as sodium and potassium). Mild fluid loss is not dangerous and is often a therapeutic goal (for example, when diuretics are used to treat high blood pressure or heart failure). However, excessive or rapid volume depletion can lead to symptoms such as dizziness, weakness, low blood pressure, and—over time—reduced kidney function. Because both empagliflozin and diuretics independently increase fluid loss, the risk of this happening is higher when they are combined.
The source record specifically calls for monitoring of renal (kidney) function. This is because the kidneys are responsible for filtering waste and regulating fluid and electrolyte balance. Excessive volume loss can reduce blood flow to the kidneys, potentially impairing their ability to filter waste and maintain balance. A simple blood test (measuring creatinine and estimated glomerular filtration rate, or eGFR) can assess whether kidney function is being affected.
While the documented interaction applies to any patient taking empagliflozin and a diuretic together, several patient groups are at higher baseline risk and should be especially diligent about medical oversight:
However, the interaction does not mean these patients should avoid the combination—only that they require closer monitoring and more frequent check-ins with their healthcare team.
Suppose a patient is prescribed empagliflozin for type 2 diabetes and is also taking a thiazide diuretic (such as hydrochlorothiazide) for high blood pressure. Both medications are reasonable choices for this patient's conditions. However, because both increase urination, the patient's doctor would likely recommend:
This monitoring does not mean the patient must stop either medication—only that oversight is necessary to catch problems early.
A patient with heart failure might be taking a loop diuretic (such as furosemide) to reduce fluid buildup in the lungs and tissues. If empagliflozin is later added to improve kidney outcomes or blood sugar control, the additive diuretic effect becomes relevant. In this case, the doctor would want to carefully watch for signs of excessive dehydration, might adjust the diuretic dose, and would monitor kidney function more frequently—because the kidneys are central to both managing heart failure and clearing fluid safely.
If you are taking (or considering taking) empagliflozin alongside a diuretic, here are science-grounded questions to raise with your healthcare team:
Do not stop or change your medications on your own. These questions are meant to guide a conversation with your doctor or pharmacist who can evaluate your personal health history and adjust your care accordingly.
This article explains a documented interaction sourced from the National Library of Medicine but is not itself a clinical recommendation. Every patient's situation is unique. Before you start, stop, or change any medication, consult with your pharmacist or physician. To check for interactions between your specific medications, visit checkdruginteractions.com and speak with your healthcare provider to confirm that your current regimen is safe and appropriate for you.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
A major documented interaction between omeprazole and methotrexate can elevate methotrexate levels. Learn what the evidence shows and wha...
Amiodarone significantly increases risk of muscle damage from simvastatin. FDA limits simvastatin to 20 mg daily with amiodarone.
FDA documentation shows ritonavir greatly increases sildenafil levels, making this combination contraindicated without strict dose limits.